The Hippo Signaling Pathway: A Candidate New Drug Target for Malignant Tumors

  • Nishio M
  • Goto H
  • Suzuki M
  • et al.
N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is a short summary of my presentation in the Uehara Memorial Foundation Symposium 2014. Classifi cation of mental illness in current diagnostic systems [such as the Diagnostic and Statistical Manual of Mental Disorders (DSM)] is built on clinical reliability and utility, but not on etiological validity. Thus, the DSM has not provided an ideal classifi cation of mental disorders. To overcome the dilemma, the National Institute of Mental Health (NIMH) recently proposed the Research Domain Criteria (RDoC) framework. This new framework emphasizes a dimensional approach on the basis of neurocircuitry mechanism. There were three aims in my presentation. First, I summarized the concept of research strategies on the basis of dimensional approach, with a link to the trajectory from early develop- ment to adolescence in the disease pathology. Second, I introduced an example of a research infrastructure that could support translational and clinical study for mental illness. Third, I showed two studies that were utilizing the infrastructure. Keywords

Cite

CITATION STYLE

APA

Nishio, M., Goto, H., Suzuki, M., Fujimoto, A., Mimori, K., & Suzuki, A. (2015). The Hippo Signaling Pathway: A Candidate New Drug Target for Malignant Tumors. In Innovative Medicine (pp. 79–94). Springer Japan. https://doi.org/10.1007/978-4-431-55651-0_7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free